8 research outputs found
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ ΠΈ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ
Backgraund:Β The result of comparative study of oropharyngeal microbiota taxonomic composition in patients with different severity level of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) is presented in this paper.Β Aims:Β To compare oropharyngeal microbiota composition in case of bronchial asthma and chronic obstructive pulmonary disease in different severity levels.Β Metods:Β 138 patients, 50 with BA and 88 with COPD were studied. For each patient was collected anamnesis vitae, swab from the back of the throat and performed physical examination. High-throughput 16S ribosomal RNA gene sequencing and bioinformatic analysis was employed to characterize the microbial communities.Β Results:Β As a result of the study was found a number of differences on various taxonomic levels in microbiotaβs composition within group of patients with different severity level of BA and group of patients with different severity level of COPD and between those groups. COPD patients with GOLD 1β2 in comparison with GOLD 3β4 patiens are marked by prevalence of species Brevibacterium aureum, genus Scardovia, Coprococcus, Haemophilus, Moryella, Dialister, Paludibacter and decrease of Prevotella melaninogenica species. BA patients with severe uncontrolled asthma in comparison with patients which have mild persistent asthma are marked by decrease of Prevotella and increase of species Bifidobacterium longum, Prevotella nanceiensis, Neisseria cinerea, Aggregatibacter segnis and genus Odoribacter, Alloiococcus, Lactobacillus, Megasphaera, Parvimonas, Sneathia. Patientβs microbiota in BA group in comparison with COPD group is characterized by the prevalence of Prevotella melaninogenica and genus Selenomonas, Granulicatella ΠΈ Gemella, and decrease of Prevotella nigrescens, Haemophilus influenza and genus Aggregatibacter, Alloiococcus, Catonella, Mycoplasma, Peptoniphilus ΠΈ Sediminibacterium. There are no differences between microbiota composition in case of severe uncontrolled BA and very severe COPD.Β Conclusion:Β Lack of differences in oropharyngeal microbiota taxonomic composition between patients with severe uncontrolled BA and very severe COPD allow us to suggest a similarity of bronchopulmonary system condition in case of diseases' severe stages.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅.Β Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΠΈ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠ΅ (ΠΠ) Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ, ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΎΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΡΡΠΎΡΠ½ΠΈΡΡ ΡΠΎΠ»Ρ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Π² ΠΈΡ
ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ:Β ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΎΡΡΠ°Π²Π° ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ ΠΏΡΠΈ Π₯ΠΠΠ ΠΈ ΠΠ ΡΠ°Π·Π½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ².Β ΠΠ΅ΡΠΎΠ΄Ρ.Β Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 138 Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΈΠ· Π½ΠΈΡ
88 Ρ Π₯ΠΠΠ, 50 β Ρ ΠΠ. ΠΠ»Ρ ΠΊΠ°ΠΆΠ΄ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π±ΡΠ» ΡΠΎΠ±ΡΠ°Π½ Π°Π½Π°ΠΌΠ½Π΅Π· ΠΆΠΈΠ·Π½ΠΈ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΠΈΠ·ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½ ΠΌΠ°Π·ΠΎΠΊ ΠΈΠ· ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ°ΠΊΡΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠ°Π²Π° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π³Π΅Π½ΠΎΠ² Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ 16SΒ ΡΠ ΠΠ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π±ΠΈΠΎΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ.Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Β ΠΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ Π±ΡΠ»ΠΈ Π½Π°ΠΉΠ΄Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ². ΠΠ»Ρ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠΠ 1β2-ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΎΠ±ΡΠ°Π·ΡΠ°ΠΌΠΈ Π₯ΠΠΠ 3β4-ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π½Π° ΡΠΎΠ½Π΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΠΈPrevotellaΒ melaninogenicaΒ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅Β BrevibacteriumΒ aureumΒ ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠΎΠ΄Π°Β Scardovia,Β Coprococcus,Β Haemophilus,Β Moryella,Β DialisterΒ ΠΈΒ Paludibacter. ΠΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΠ° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ ΠΏΡΠΈ Π»Π΅Π³ΠΊΠΎΠΉ ΠΏΠ΅ΡΡΠΈΡΡΠΈΡΡΡΡΠ΅ΠΉ ΡΠΎΡΠΌΠ΅ Π½Π° ΡΠΎΠ½Π΅ Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ ΡΠΎΠ΄Π°Β PrevotellaΒ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ΠΌΒ BifidobacteriumΒ longum,Β PrevotellaΒ nanceiensis,Β NeisseriaΒ cinerea,Β AggregatibacterΒ segnis, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠΎΠ΄Π°Β Odoribacter,Β Alloiococcus,Β Lactobacillus,Β Megasphaera,Β ParvimonasΒ ΠΈΒ Sneathia. ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ ΠΈ Π₯ΠΠΠ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ ΠΎΡΠΌΠ΅ΡΠ°Π»Π°ΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ°Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΡΒ P.Β melaninogenicaΒ ΠΈ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠΎΠ΄Π°Β Selenomonas,Β Granulicatella,Β Gemella, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅Β PrevotellaΒ nigrescens,Β HaemophilusΒ influenzaeΒ ΠΈΒ Aggregatibacter,Β Alloiococcus,Β Catonella,Β Mycoplasma,Β Peptoniphilus,Β Sediminibacterium. ΠΡΠΈ ΡΡΠΎΠΌ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΆΠ΅Π»ΠΎΠΉ Π½Π΅ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠΉ ΠΠ ΠΈ Π₯ΠΠΠ ΠΎΡΠ΅Π½Ρ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½Ρ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.Β ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΠΈ ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Π₯ΠΠΠ ΠΈ ΠΠ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π²ΡΡΠΊΠ°Π·Π°ΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΎ ΡΡ
ΠΎΠ΄ΡΡΠ²Π΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ Π±ΡΠΎΠ½Ρ
ΠΎΠ»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΠΈ ΡΡΠΆΠ΅Π»ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΡΠ°Π·Π²ΠΈΡΠΈΡ Π΄Π°Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
Semi-coking of oil shale of the Leningrad deposit
Recently, there has been a growing global interest in processing low-grade types of solid fuels, such as oil shale. In the near future, the role of solid fuels in the country's fuel and energy balance is expected to increase, primarily due to their large reserves. Based on this, this work evaluates the semi β coke obtained by semi-coking low-grade types of solid combustible fossils-oil shale of the Baltic basin (Leningrad deposit). The influence of process parameters (temperature and holding time) on the physical and chemical properties of shale semi-coke was studied experimentally. Based on the data obtained, it is concluded that the obtained samples of semi-coke from oil shale and brown coal can be used as a substitute for coke in various industries and the national economy
ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² FYN, ZAP-70 ΠΈ LAT ΠΏΡΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ
Background: Bronchial asthma (BA) is one of the most spreading chronic lung pathology in the world. The disease is characterized by high heterogeneity of clinical phenotypes including resistant forms which provoke significant clinical problem. Immune shift from Th2 to alternative immunological response is considered to be a mechanism of drug-resistance in BA treatment but this issue is not considerably studied yet. Aims: Detection of distinctive patterns in cytokine secretion and genetic expression (ZAP-70, FYN and LAT) of naΓ―ve and concanavalin A stimulated lymphocytes in patients with resistant BA. Materials and methods: The study enrolled ten patients in each group: subjects with treatment resistant BA, severe BA, and controls (30 in total). During the experiment, all patients with BA received treatment according to the condition. For each participant lymphocytes isolation from venous blood was performed. Cells were cultured with concanavalin A and without stimulation. Concentrations of cytokines IL-2, IL-12, TNF-Ξ±, IL-4, IL-5, and IL-6 in supernatants were measured with ELISA. Reverse transcription polymerase chain reaction was used to detect the mRNA expression of LAT, ZAP-70, and FYN genes. Results: Significant disease contribution to the lymphocyte secretion profile was established without concanavalin A stimulation: increased levels of IL-2 and IL-4 was observed in lymphocytes of patients with resistant BA if compared to the results of gorup with severe BA. Patients with resistant BA were characterized by weak cytokine response to the stimulation: only TNF-Ξ± and IL-5 levels were significantly increased whereas in group with severe BA all cytokines concentrations increased except IL-12, in controls β except IL-12 and IL-2. Significant FYN upregulation was identified in resistant BA group if compared with other groups, and in severe BA patients if compared with controls. The concanavalin A-stimulated cells showed increased expression of ZAP-70 in cells of patients with resistant BA compared to control group. Conclusions: Lymphocytes from patients with resistant BA are characterized by lack of cytokine response to concanavalin A stimulation, alteration of cytokine secretion, and genetic expression profile similar to cells with low sensitivity to apoptosis. The FYN gene is a perspective target for finding approaches to overcome resistance to steroid drugs in bronchial asthma.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½Π°Ρ Π°ΡΡΠΌΠ° (ΠΠ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΡΠΎΠ½Ρ
ΠΎΠ»Π΅Π³ΠΎΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΡΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΠΏΠΎΠ»ΠΈΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ½ΠΎΡΡΡΡ ΠΈ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ: ΡΡΡΠ΅ΡΡΠ²ΡΡΡ ΡΠ΅Π½ΠΎΡΠΈΠΏΡ Π°ΡΡΠΌΡ, ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡΠΈΠ΅ ΡΠ΅ΡΡΠ΅Π·Π½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° Π΄Π°Π½Π½ΡΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅ΡΡΡ Β«ΠΏΠ΅ΡΠ΅ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅Β» ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Ρ Th2 Π½Π° Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΏΡΠΈΡΠΈΠ½Ρ ΡΡΠΎΠ³ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΏΠΎΠ½ΡΡΠ½Ρ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠΌΠ°, Π³Π΅Π½Ρ ZAP-70, FYN ΠΈ LAT ΠΌΠΎΠ³ΡΡ ΠΈΠ³ΡΠ°ΡΡ ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΡ
ΠΏΠ°ΡΡΠ΅ΡΠ½ΠΎΠ² ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΠΎΠΉ ΡΠ΅ΠΊΡΠ΅ΡΠΈΠΈ ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² (ZAP-70, FYN ΠΈ LAT) ΠΈΠ½ΡΠ°ΠΊΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΏΡΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π ΠΏΡΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ. ΠΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ ΠΏΠΎ 10 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ 10 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π·Π°Π±ΠΎΡΠ° ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΠ. Π£ ΠΊΠ°ΠΆΠ΄ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π·Π°Π±ΠΎΡ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠΉ ΡΡΠ°ΠΊΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈ Ρ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π ΠΈ Π±Π΅Π· Π½Π΅Π³ΠΎ. ΠΠΎΡΠ»Π΅ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² IL2, IL12, TNFΞ±, IL4, IL5 ΠΈ IL6 Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½ΠΎΠ² LAT, ZAP-70 ΠΈ FYN ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠ΅ΠΊΡΠ΅ΡΠΈΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π±Π΅Π· ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π. Π ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ ΠΏΠΎΠ²ΡΡΠ°Π»Π°ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ IL2 ΠΈ IL4 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ. ΠΠΈΠΌΡΠΎΡΠΈΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΡΠΉ ΠΎΡΠ²Π΅Ρ Π½Π° ΡΡΠΈΠΌΡΠ»ΡΡΠΈΡ: ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ Π»ΠΈΡΡ IL5 ΠΈ TNFΞ±, ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ ΠΏΠΎΠ²ΡΡΠ°Π»Π°ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ Π²ΡΠ΅Ρ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ IL12, Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ β Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ IL12 ΠΈ IL2. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ FYN Π² Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ Π²Π½Π΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠ΅ΠΆΠΈΠΌΠ° ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ ΠΈ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π³Π΅Π½Π° Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΠΠ. Π’Π°ΠΊΠΆΠ΅ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ZAP-70 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΠΏΡΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½Π°Ρ ΡΡΠ°ΠΊΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΡΠ»Π°Π±ΡΠΌ ΠΎΡΠ²Π΅ΡΠΎΠΌ Π½Π° ΡΡΠΈΠΌΡΠ»ΡΡΠΈΡ ΠΊΠΎΠ½ΠΊΠ°Π½Π°Π²Π°Π»ΠΈΠ½ΠΎΠΌ Π, ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΠΌ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΌ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΠΎΠΉ ΡΠ΅ΠΊΡΠ΅ΡΠΈΠΈ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ Π΄Π»Ρ ΠΊΠ»Π΅ΡΠΎΠΊ Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ ΠΏΡΠΎΠ°ΠΏΠΎΠΏΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΠΈΠΌΡΠ»Π°ΠΌ. ΠΠ΅Π½ FYN ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΡΡ Π΄Π»Ρ ΠΏΠΎΠΈΡΠΊΠ° ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΏΠΎ ΠΏΡΠ΅ΠΎΠ΄ΠΎΠ»Π΅Π½ΠΈΡ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ ΠΏΡΠΈ ΠΠ
Standardization of bee venom as a raw material for the production of medicines for immunotherapy, including allergen and allergoid from bee venom [Π‘ΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠ΅Π»ΠΈΠ½ΠΎΠ³ΠΎ ΡΠ΄Π° ΠΊΠ°ΠΊ ΡΡΡΡΡ Π΄Π»Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² Π΄Π»Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π°Π»Π»Π΅ΡΠ³Π΅Π½Π° ΠΈ Π°Π»Π»Π΅ΡΠ³ΠΎΠΈΠ΄Π° ΠΈΠ· ΠΏΡΠ΅Π»ΠΈΠ½ΠΎΠ³ΠΎ ΡΠ΄Π°]
Introduction. Pharmaceutical industry widely uses beekeeping products to obtain medicines. Among beekeeping products for medical use, bee venom represents number three on its importance. Pharmaceuticals based on bee venom are used externally, or as injections, or for oral administration. In the production of medicines containing bee venom, it is important to take into account the dose and possible individual response of the human body. The chemical composition of raw bee venom is very complex. Currently, there is no modern normative documentation for standardization of bee venom as a raw material for pharmaceutical preparations. Hence, quality control and standardization of the substance of bee venom intended for the production of medicines represent the urgent need. Aim of research is to study the physicochemical characteristics of raw bee venom of various batches in order to evaluate and standardize its quality. Material and methods. We have studied 5 batches of raw bee venom from the same manufacturer. The analysis was carried out on the basis of GOST 30426-97 Methods of purification and standardization of purified bee venom were developed in this study. Those included gel chromatography and PAAG electrophoresis. Results. According to the results of studies of raw bee venom, 4 batches of 5 did not correspond the requirements of the GOST 30426-97 in terms of mass fraction of water-insoluble impurities (6.01 %); mass fraction of water (9.17 %); hemolysis time (300 s), mass fraction of melittin and apamin (35 %; 0.6 %), respectively. Methods for the purification and standardization of preparations from raw bee venom were suggested. Conclusion. In our study, we have proven the low level of the standardization of raw poison. The lack of approved normative documents leads to the fact that different pharmaceutical companies use different methods for evaluating the quality of raw materials and methods for their purification, which, in turn, affects the quality of final pharmaceutical products. Therefore the part of General Pharmacopoeia Β«Raw Bee PoisonΒ» (related to standardization of raw materials from which pharmaceuticals are being obtained) should be developed. Β© 2021 Meditsina Publishers. All rights reserved
Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a suitable target for specific delivery of antitumor drugs and diagnostic agents due to its overexpression in prostate cancer cells. In the current work, we describe the design, synthesis, and biological evaluation of novel low-molecular PSMA ligands and conjugates with fluorescent dyes FAM-5, SulfoCy5, and SulfoCy7. In vitro evaluation of synthesized PSMA ligands on the activity of PSMA shows that the addition of aromatic amino acids into a linker structure leads to a significant increase in inhibition. The conjugates of the most potent ligand with FAM-5 as well as SulfoCy5 demonstrated high affinities to PSMA-expressing tumor cells in vitro. In vivo biodistribution in 22Rv1 xenografts in Balb/c nude mice of PSMA-SulfoCy5 and PSMA-SulfoCy7 conjugates with a novel PSMA ligand demonstrated good visualization of PSMA-expressing tumors. Also, the conjugate PSMA-SulfoCy7 demonstrated the absence of any explicit toxicity up to 87.9 mg/kg. Β© 2021 American Chemical Society. All rights reserved